Objective IF-EBOLA has been strategically designed to efficiently respond to critical needs required to control Ebola outbreak from spreading and prepare a therapeutic approach to save lives. The work involves two of the main EVD outbreak sites, Sierra Leone and Liberia. MDs, public health authorities and virus experts working on site, under ethical regulatory rules, will extend their collaboration to companies and institutions to form a consortium of outstanding complementary partners, sharing their innovative technological approaches for a common goal.The main goal of our project is to contribute to provide innovative ultrasensitive diagnostics and therapeutic approaches for an early and accurate diagnostic for an early therapeutic treatment to control the epidemic and safe lives. We have been obligated to modify and extend for one year our initial two-year period IF-EBOLA action program due to both major foreseen and unforeseen changes produced during this “non-emergency” period: consisting mainly now in 3 main actions: (i) Preclinical validation of the therapeutic equine anti-Ebola antibodies; (ii) Clinical validation of the ultrasensitive detection (iii) homeostasis (“pathology”) profiling of patients and survivors. Originally (“emergency period”) IF-EBOLA included 2 phases: (I) a phase of preparation including, ethical authorizations, antibody production, technical and field organization as well as the beginning a follow-up of the homeostatic profile of contacts early-EBOV diagnosed and self-cured convalescent individuals in the absence of existing treatment, (with an ultrasensitive detection method of pernicious microorganisms, from the EC USDEP project qualified as a European success story “USDEP” project in 2010 by the EC-Project Officer) and (II) phase of a clinical study using a wide validated approach revisited with an innovative concept (strongly supported EC/EMA-WHO), we propose to carry out an experimental passive-immune therapy based on neutralizing capacity of horse anti-EBOV polyclonal F(ab’)2 on early-diagnosed patients to impact and reduce their pre-existing viremia, their mortality, the evolution of their homeostasis profile, during and after this treatment (once patients become convalescents). The homeostasis status evolution will help to generate high quality scientific data to understand the EVD, the effect of this therapy and cure parameters characterized at 3 different levels: immune (transcriptomes, NGS, metagenomics); infectious (other than EBOV, DNA arrays), and EBOV diversity (sequencing and metagenomics). Fields of science medical and health scienceshealth sciencespublic healthmedical and health scienceshealth sciencesinfectious diseasesRNA virusesebolamedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesbasic medicinephysiologyhomeostasismedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantivirals Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme Topic(s) Health - Health Call for proposal H2020-Adhoc-2014-20 See other projects for this call Funding Scheme RIA - Research and Innovation action Coordinator INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT Net EU contribution € 360 895,00 Address Boulevard de dunkerque 44 cs 90009 13572 Marseille France See on map Region Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 Participants (8) Sort alphabetically Sort by Net EU contribution Expand all Collapse all BEN-GURION UNIVERSITY OF THE NEGEV Israel Net EU contribution € 199 350,00 Address . 84105 Beer sheva See on map Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO Italy Net EU contribution € 52 700,00 Address Via portuense, 292 00149 Roma See on map Region Centro (IT) Lazio Roma Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 INSTITUT PASTEUR France Net EU contribution € 127 075,00 Address Rue du docteur roux 25-28 75724 Paris See on map Region Ile-de-France Ile-de-France Paris Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 FABENTECH France Net EU contribution € 972 750,00 Address 24 rue jean baldassini immeuble tony garnier 69007 Lyon See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Auvergne-Rhône-Alpes Rhône-Alpes Rhône Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 UNIVERSITY OF MANITOBA Canada Net EU contribution € 0,00 Address Administration building room 202 R3T 2N2 Manitoba See on map Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 45 000,00 METABIOTA INC Participation ended United States Net EU contribution € 100 000,00 Address 1 sutter suite 600 94104 San francisco See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 ORION INTEGRATED BIOSCIENCES INC. United States Net EU contribution € 135 000,00 Address 265 centre ave 10805 New rochelle See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 ABSISKEY France Net EU contribution € 45 000,00 Address 41b rue dupetit thouars 49000 Angers See on map Region Pays de la Loire Pays de la Loire Maine-et-Loire Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
